Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Clinical trial NCT05181033 · RECRUITING
Trial details
- NCT number
- NCT05181033
- Sponsor
- National University Hospital, Singapore
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-27
- Primary completion
- 2027-08-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.